BC Week In Review | Jul 25, 2005
Clinical News

RC-8800: Phase I started

Rejuvenon began a dose-escalation, U.S. Phase I trial in 8 to 12 healthy subjects. Rejuvenon Corp. , Houston, Texas   Product: RC-8800   Business: Cancer   Molecular target: 24-hydroxylase   Description: Small molecule that acts on...
BC Week In Review | May 3, 2004
Company News

University of Wisconsin other research news

Researchers published in the Proceedings of the National Academy of Sciences that in rats, specific vitamin D analogs showed little or no increase in serum calcium concentration but significantly suppressed parathyroid hormone levels (p<0.05) and...
Items per page:
1 - 2 of 2